Plasma ceramides highlighted in European Heart Journal

European Heart Journal recently highlighted Zora's invention, new blood test that predicts cardiovascular events in patients with or without coronary artery disease. The test is…

Read more

Mayo Clinic will present plasma ceramide results at ACC 2017

The CERAM test, released commercially by Mayo Medical Laboratories in August 2016, measures blood concentrations of plasma ceramides, a class of lipids that are highly…

Read more

What are plasma ceramides?

Learn what are plasma ceramides and why you should measure your ceramides. Watch Dr. Jeff Meeusen’s informative video on plasma ceramides and their relation to…

Read more

Heart Attack Risk Test, CERT, is available from various medical centers in Finland

Heart Attack Risk Test, CERT, is available from various medical centers in Finland CERT-test measures persons risk of getting a heart attack or even heart-related…

Read more

Coronary Event Risk Test available in Finland through United Medix Laboratories

Ceramides, Coronary Event Risk Test, CERT Coronary Event Risk Test, CERT, is a new diagnostic test for evaluation of risk of heart attack and CVD-related…

Read more

We are hiring – Join Zora-team

Zora Biosciences is looking for a Bioinformatician Zora Biosciences Oy is a discovery diagnostics company. Zora identifies, validates and develops novel clinical tools using a…

Read more

Plasma Ceramide test is now available at Mayo Clinic Medical Laboratories

Plasma Ceramides predict adverse cardiovascular events. Elevated plasma ceramide concentrations are risk factors for cardiovascular mortality, myocardial infarction and acute coronary syndrome hospitalizations. Plasma ceramides…

Read more

Zora and Mayo Medical Laboratories to collaborate on Plasma Ceramide Testing

Zora and Mayo Medical Laboratories  has signed Collaborate on Plasma Ceramides Testing.  The test will be launched in summer, and is used to predict adverse…

Read more

Zora at EAS 2016 Innsbruck

Zora participates 84th EAS Congress at Innsbruck, Austria. Our CMO Reijo Laaksonen presents our latest results on cardiovascular risk prediction in statin treated patients at…

Read more

Zora at Nature Reviews Research Highlights

Zora's recent publication on CERT was reviewed in Nature Reviews Cardiology Research Highlights. Read the research highlight here.

Read more

New biomarker for identification of coronary artery disease patients at high risk for cardiovascular death

Zora Biosciences in collaboration with academic research groups from Finland, Germany, Austria,  Switzerland and Norway have shown that plasma ceramides are significant predictors of cardiovascular…

Read more

Zora has updated visual identity

We have renewed our visual identity. Zora logo is now modernized. Inspiration for the new logo comes from the six carbon ring that is commonly…

Read more